Diet-induced obesity predisposes anti-PD-1 antibody-treated mice to imiquimod-mediated psoriasiform dermatitis: implications for immune-related adverse events in cancer patients treated with anti-PD-1

被引：0
|
作者：
Yu, S. [1 ,2 ]
Wu, X. [2 ]
Shi, Z. [2 ]
Huynh, M. [2 ]
Hwang, S. T. [2 ]
机构：
[1] Kaohsiung Med Univ, Dept Dermatol, Kaohsiung, Taiwan
[2] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2019年 / 139卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
022
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [21] Receipt of Chest Radiation and Immune-Related Pneumonitis in Patients with NSCLC Treated with Anti-PD-1/PD-L1
    Voong, K. R.
    Hazell, S.
    Hu, C.
    Hayman, J.
    Hales, R.
    Marrone, K.
    Hann, C.
    Ettinger, D.
    Feliciano, J.
    Rowe, V.
    Kelly, R.
    Brahmer, J.
    Forde, P.
    Naidoo, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1837 - S1837
  • [22] Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment
    Passat, Tilda
    Touchefeu, Yann
    Gervois, Nadine
    Jarry, Anne
    Bossard, Celine
    Bennouna, Jaafar
    BULLETIN DU CANCER, 2018, 105 (11) : 1033 - 1041
  • [23] Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy
    Hsu, Shu-Jung
    Chao, Yen-Cheng
    Lin, Xia-Hui
    Liu, Hua-Hua
    Zhang, Yang
    Hong, Wei-Feng
    Chen, Mao-Pei
    Xu, Xin
    Zhang, Lan
    Ren, Zheng-Gang
    Du, Shi-Suo
    Chen, Rong-Xin
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2023, 212 (03): : 239 - 248
  • [24] Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
    Sebestyen, Eniko
    Major, Nora
    Bodoki, Levente
    Makai, Attila
    Balogh, Ingrid
    Toth, Gabor
    Orosz, Zsuzsanna
    Arkosy, Peter
    Vasko, Attila
    Hodosi, Katalin
    Szekanecz, Zoltan
    Szekanecz, Eva
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
    Zhao, Zhe
    Wang, Xinfeng
    Qu, Jinghan
    Zuo, Wei
    Tang, Yan
    Zhu, Huijuan
    Chen, Xiaoguang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
    Rogado, Jacobo
    Romero-Laorden, Nuria
    Miguel Sanchez-Torres, Jose
    Maria Ramos-Levi, Ana
    Pacheco-Barcia, Vilma
    Isabel Ballesteros, Ana
    Arranz, Reyes
    Lorenzo, Alicia
    Gullon, Pedro
    Garrido, Ana
    Serra Lopez-Matencio, Jose Maria
    Donnay, Olga
    Adrados, Magdalena
    Costas, Pablo
    Aspa, Javier
    Alfranca, Arantzazu
    Mondejar, Rebeca
    Colomer, Ramon
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [27] Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition
    Goswami, Meghali
    Gui, Gege
    Lindblad, Katherine
    Del Rivero, Jaydira
    Marte, Jennifer
    Dagur, Pradeep
    Destefano, Christin
    Thompson, Julie
    Popescu, Bogdan
    Dillon, Laura
    Johnson, Cheryl
    Soldin, Steven
    Lai, Catherine
    Gulley, James
    Hourigan, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [28] Sarcopenia predicts immune-related adverse events due to anti-PD-1/PD-L1 therapy in patients with advanced lung cancer
    Xue, Dinglong
    Li, Ning
    Yang, Jiaxin
    Men, Kaiya
    Li, Lijun
    Jiang, Hao
    Zhao, Xu
    Zhang, Shuai
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [29] Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
    Baxi, Shrujal
    Yang, Annie
    Gennarelli, Renee L.
    Khan, Niloufer
    Wang, Ziwei
    Boyce, Lindsay
    Korenstein, Deborah
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 360
  • [30] Autoantibody profiling for predictive biomarkers for immune-related adverse events and clinical benefit in rare tumors treated with anti-PD-1 therapy
    Derbala, Mohamed H.
    Hajjar, Joud
    Stephen, Bettzy
    Gurses, Serdar A.
    Kwiatkowski, Evan
    Budde, Petra
    Zucht, Hans-Dieter
    Brautigam, Manuel
    Schubert, Ann-Sophie
    Ahangarianabhari, Behnaz
    Rodriguez, Enedelia
    Gouda, Mohamed
    Castillo, Lilibeth
    Zarifa, Abdulrazzak
    How, Jeffrey A.
    Moyers, Justin T.
    Hong, David S.
    Meric-Bernstam, Funda
    Naing, Aung
    CANCER RESEARCH, 2024, 84 (06)
12345